T.E. Dufresne
Procter & Gamble
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by T.E. Dufresne.
Calcified Tissue International | 2003
T.E. Dufresne; Paula A. Chmielewski; Michael D. Manhart; T. D. Johnson; Babul Borah
Risedronate reduces the risk of vertebral fractures by up to 70% within the first year of treatment. Increases in bone mineral density or decreases in bone turnover markers explain only a portion of the anti-fracture effect, suggesting that other factors, such as changes in trabecular bone architecture, also play a role. Our objective was to determine the effects of risedronate on bone architecture by analyzing iliac crest bone biopsy specimens using three-dimensional microcomputed tomography (3-D µCT). Biopsy specimens were obtained at baseline and after 1 year of treatment from women enrolled in a double-blind, placebo-controlled study of risedronate 5 mg daily for the prevention of early postmenopausal bone loss. Trabecular architecture deteriorated in the placebo group (n = 12), as indicated by a 20.3% decrease in bone volume (25.1% vs. 20.0%, P = 0.034), a 13.5% decrease in trabecular number (1.649 vs. 1.426 mm−1, P = 0.052), a 13.1% increase in trabecular separation (605 vs. 684 µm, P = 0.056), and an 86.2% increase in marrow star volume (3.251 vs. 6.053 mm3, P = 0.040) compared with baseline values. These changes in architectural parameters occurred in the presence of a concomitant decrease from baseline in lumbar spine bone mineral density (−3.3%, P = 0.002), as measured by dual energy x-ray absorptiometry. There was no statistically significant (P < 0.05) deterioration in the risedronate-treated group (n = 14) over the 1-year treatment period. Comparing the actual changes between the two groups, the placebo group experienced decreases in bone volume (placebo, −5.1%; risedronate, +3.5%; P = 0.011), trabecular thickness (placebo, −20 µm; risedronate, +23 µm; P = 0.032), and trabecular number (placebo, −0.223 mm−1; risedronate, +0.099 mm−1; P = 0.010), and increases in percent plate (placebo, +2.79%; risedronate, −3.23%; P = 0.018), trabecular separation (placebo, +79 µm; risedronate, −46 µm; P = 0.010) and marrow star volume (placebo, +2.80 mm3 ; risedronate, −2.08mm3; P = 0.036), compared with the risedronate group. These data demonstrate that trabecular architecture deteriorated significantly in this cohort of early postmenopausal women, and that this deterioration was prevented by risedronate. Although there is no direct link in this study between fracture and preservation of architecture, it is reasonable to infer that the preservation of bone architecture may play a role in risedronate’s anti-fracture efficacy.
Journal of Bone and Mineral Research | 2000
Babul Borah; T.E. Dufresne; M. D. Cockman; Gary Gross; E. W. Sod; W. R. Myers; K. S. Combs; R. E. Higgins; S. A. Pierce; M. L. Stevens
The study objective was to analyze the three‐dimensional (3D) trabecular architecture and mechanical properties in vertebral specimens of young and mature Sinclair minipigs to assess the relative contribution of architecture to bone strength. We used 3D magnetic resonance microimaging (MRμI) and direct image analysis to evaluate a set of standard structural measurements and new architectural descriptors of trabecular bone in biopsy specimens from L2, L3, and L4 vertebrae (n = 16 in each group) from young (mean age, 1.2 years) and mature (mean age, 4.8 years) minipigs. The measurements included bone volume/tissue volume (BV/TV), marrow star volume (Ma.St.V), connectivity density (ConnD), and two new parameters, percent platelike trabeculae (% plate) and percent bone in the load direction (% boneLD). The % plate, calculated from surface curvature, allowed the delineation of plates from rods. The % boneLD quantified the percentage of bone oriented along the long axis of the vertebral body. We showed that 3D MRμI can detect the subtle changes in trabecular architecture between the two age groups. ConnD, star volume, % plate, % boneLD, and BV/TV were found to be more effective than the model‐based, derived indices (trabecular thickness [Tb.Th], trabecular separation [Tb.Sp], and trabecular number [Tb.N]) in differentiating the structural changes. BV/TV, % plate, and % boneLD significantly increased (p < 0.05) in all three vertebral sites of the mature minipigs. The significant decrease in ConnD and star volume in the mature vertebra was consistent with the concurrent increase of platelike trabecular bone (p < 0.05). Overall, ConnD, star volume, % plate, and % boneLD provided a coherent picture of the architectural changes between the two age groups. Apparent modulus and maximum stress were determined experimentally on biopsy specimens from L2 vertebrae (n = 16). When apparent modulus was predicted using 3D MRμI data sets as input for finite element modeling (FEM), the results were similar to the experimentally determined apparent modulus (p = 0.12). Both methods were then used to compare the young and the mature animals; the experimental and predicted apparent modulus were significantly higher for the mature group (p = 0.003 and 0.012, respectively). The experimental maximum stress in the vertebra of the mature animals was twice as high as that for the young animals (p = 0.006). Bone quantity (BV/TV or bone mineral content [BMC]) alone could explain approximately 74–85% of the total variability in stress and modulus. The inclusion of either ConnD or % boneLD with BV/TV in a multiple regression analysis significantly improved the predictability of maximum stress, indicating that architecture makes additional contributions to compressive strength in normal minipig vertebra.
Bone | 2006
Babul Borah; T.E. Dufresne; Erik L. Ritman; Steven M. Jorgensen; S. Liu; Paula A. Chmielewski; Roger Phipps; Xiaojie Zhou; Jean Sibonga; Russell T. Turner
Bone | 2010
Babul Borah; T.E. Dufresne; Joe Nurre; Paula A. Chmielewski; Roger Phipps; Leigh Mccullough; Mary L. Bouxsein; Roger Zebaze; Ego Seeman
Archive | 2015
Michael Sean Pratt; Min Mao; David C. Oertel; Janine Anne Flood; T.E. Dufresne; Paula A. Chmielewski; Andreas Josef Dreher; Alyssandrea Hope Hamad-Ebrahimpour
Archive | 2015
David C. Oertel; Janine Anne Flood; T.E. Dufresne; Paula A. Chmielewski; Andreas Josef Dreher; Alyssandrea Hope Ebrahimpour; Paul Thomas Weisman; Michael Sean Pratt; Min Mao
Bone | 2009
Babul Borah; T.E. Dufresne; Joe Nurre; Paula A. Chmielewski; Roger Phipps; Leigh K. Wagner; Mary L. Bouxsein; Roger Zebaze; Ego Seeman
Bone | 2009
Babul Borah; Joe Nurre; Paula A. Chmielewski; T.E. Dufresne; Leigh K. Wagner
Bone | 2008
T.E. Dufresne; Paula A. Chmielewski; Joe Nurre; Babul Borah; Xiaojie Zhou; Roger Phipps; G. Woodson; P.D. Miller
Calcified Tissue International | 2003
T.E. Dufresne; Paula A. Chmielewski; Michael D. Manhart; T. D. Johnson; Babul Borah